Loading data for BCAX — first visit, this takes a few seconds.

提醒

Bicara Therapeutics Inc. (BCAX)

NasdaqGM: BCAX · 即時價格 · USD

23.43

-1.40 (-5.64%)

收盤價： Aug 28, 2026, 3:59 PM

23.43

+0.00%

盤後: 7:30 PM

股價、關鍵數字和最新消息，都在這一頁。

-5.64% (1D)

買價	18.74
市值	1.55B
營收 (ttm)	n/a
淨利（ttm）	-185.36M
	n/a
	-2.9
	n/a
	-6.82
P/B (ttm)	3.30
P/S (ttm)	n/a
財報日期	Nov 10, 2026

賣價	32.75
成交量	524,734
20 日平均成交量	727,660
開盤價	24.56
前收盤價	24.83
當日區間	23.36 - 24.56
52 週範圍	10.29 - 30.99
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 BCAX

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massac...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Sep 13, 2024

員工 103

證券交易所 NasdaqGM

股票代號 BCAX

網站 https://www.bicara.com

完整的公司簡介

財務表現

Bicara Therapeutics 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -137.95M，較前期增加 102.88%。

財務報表

財報驚奇

Bicara Therapeutics 已於 Aug 11, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -0.82 超出預期 0.01, 年增 -64.00% 下滑.

下次財報發布

Bicara Therapeutics Inc. 的下次財報預計於 Nov 10, 2026, 開盤前。
分析師預估營收 ... 升級

新聞動態

1 週前 · Insider Monkey

Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul

On August 11, Bicara Therapeutics (NASDAQ:BCAX) used its second-quarter earnings call to deliver two headlines at once. CEO Claire Mazumdar announced she will step into a Vice Chair and Strategic Advi...

1 週前 · Motley Fool

Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript

Cash runway extends to 2029 as ficerafusp alfa advances toward interim analysis.

2 週前 · Simply Wall St.

Leadership Shake-Up And Ficerafusp Alfa Milestone Timeline Might Change The Case For Investing In Bicara Therapeutics (BCAX)

Bicara Therapeutics recently reported second-quarter 2026 results showing a wider net loss of US$55.44 million and higher loss per share, alongside filing a US$19.41 million employee stock offering sh...

2 週前 · MT Newswires

Bicara Therapeutics' Cancer Study On Track for 2026 Enrollment, Wedbush Says

Bicara Therapeutics (BCAX) pivotal Fortifi-HN01 study in first-line recurrent/metastatic HPV-negativ

2 週前 · Moby

Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary

Moby summary of Bicara Therapeutics Inc. Common Stock's Q2 2026 earnings call

第 1 頁，共 2 頁

Bicara Therapeutics Inc. (BCAX)